To address the risk of on-target, off-tumor toxicity from ErbB expression in normal tissues, ErbB-targeted CARs that detect tumor hypoxia offer a promising solution, selectively targeting tumor cells while sparing healthy tissues [87]. This evidence concerns the gene EGFR and neoplasm.